DISC MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.66 USD | +1.11% |
|
+7.07% | -39.99% |
| 05-09 | Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-08 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
Presenter SpeechDouglas Tsao (Analysts)Welcome, everybody. I'm Doug Tsao, senior analyst at H....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Calendar
12/06/2024
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
34.66
USD
Average target price
57.33
USD
Spread / Average Target
+65.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.99% | 847M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
- Stock Market
- Equities
- IRON Stock
- News Disc Medicine, Inc.
- Transcript : Disc Medicine Opco Inc Presents at H.C. Wainwright BioConnect Investor Conference at Nasdaq 2023, May-02-2023 02
